

Ref no: 017040919
From: Public
Date: 04/09/19
Subject: Dermatitis and asthma

REQUEST & RESPONSE

1. How many patients were treated, in the last 3 months available for moderate or severe atopic dermatitis?

Less than 5 patients were diagnosed with moderate or severe atopic dermatitis following an inpatient stay.

Of these treated patients how many are paediatric?

Less than 5 patients were classed as paediatric.

2. How many patients were treated, in the last 3 months available for moderate or severe atopic dermatitis with the following drugs?

Acitretin
Alitretinoin
Pimecrolimus
Tacrolimus
Dupilumab [Dupixent]
Etanercept
Infliximab
Adalimumab
Ustekinumab

Only the following drugs are coded: **Etanercept, Infliximab, Adalimumab, Ustekinumab**

No patients had a code of Etanercept, Infliximab, Adalimumab or Ustekinumab.

3. How many patients aged 18 and over, were treated in the last 3 months available for asthma?

2387 patients aged 18 and over diagnosed with asthma following an inpatient stay.

4. How many patients aged 17 and under, were treated in the last 3 months available for asthma?

123 patients aged 17 and under diagnosed with asthma following an inpatient stay.

5. How many asthma patients were treated in the last 3 months available with:

Omalizumab [Xolair]
Mepolizumab [Nucala]
Reslizumab [Cinqaero]
Benralizumab [Fasenra]

Only the following drugs are coded: Omalizumab [Xolair]

No patients had a code of Omalizumab [Xolair].

6. How many paediatric severe asthma patients have been treated with Xolair/omalizumab in the last 3 months available?

No paediatric patients with severe asthma had a code of Omalizumab [Xolair].

7. How many chronic spontaneous urticaria (CSU) patients have been treated with Xolair/omalizumab in the last 3 months available?

No patients with chronic urticaria had a code of Omalizumab [Xolair].